DO-BO

What does the future hold for AI in Healthcare, Aleksey Zavgorodniy?

What will the future of AI in healthcare look like? Join us in the latest episode of MAP, the Market Access Podcast, featuring Alexey Zavgorodniy from Unicsoft, and explore the transformative world of artificial intelligence. With extensive experience in AI and large language models, Alexey shares invaluable insights into how AI is reshaping healthcare, pharmaceuticals, and beyond.

In this episode you will learn how AI mirrors the industrial revolution and how that results in both unique opportunities and challenges. Aleksey also illustrates some real-world applications of AI in market access, from predictive analytics in drug pricing to automated literature reviews and more. 

The discussion also goes further into the importance of privacy and ethical considerations that follows AI use, and why it is necessary to ensure data security while maximizing the benefits of technology

Whether you’re an industry professional or a tech enthusiast, this episode offers a comprehensive overview of AI’s current applications and its potential to drive future innovations in healthcare.

Related

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer speaks with Sreeram Ramagopalan, a global expert at the intersection of biotech value, HTA, real‑world evidence and market access. Together they unpack how the UK NICE threshold increase (from £20–30k to £25–35k per QALY) and US reforms (IRA, MFN) are quietly […]

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer engages with Swiss healthcare strategist Cuno Moser to explore Europe’s “innovation paradox” in healthcare. Despite its strengths in research, data quality, and clinical expertise, Europe struggles to transform pilot projects into scalable, reimbursable solutions. With over 27 fragmented reimbursement systems in […]

In the latest episode of the MAP – Market Access Podcast, Dr. Stefan Walzer speaks with pricing and access expert Shrutya Bhalla about how primary research must evolve in an era of AI, policy shocks, and accelerating market complexity. The key takeaway: high‑quality primary research is no longer just about collecting insights – it must […]